Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
But the former is paying a fraction of what Merck shelled out for raludotatug.
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
